  Tissue plasminogen activator (tPA) is the sole approved therapeutic molecule
for the treatment of acute ischemic stroke. Yet, only a small percentage of
patients could benefit from this life-saving treatment because of medical
contraindications and severe side effects, including brain hemorrhage,
associated with delayed administration. Here, a nano therapeutic agent is
realized by directly associating the clinical formulation of tPA to the porous
structure of soft discoidal polymeric nanoconstructs (tPA-DPNs). The porous
matrix of DPNs protects tPA from rapid degradation, allowing tPA-DPNs to
preserve over 70 % of the tPA original activity after 3 h of exposure to serum
proteins. Under dynamic conditions, tPA-DPNs dissolve clots more efficiently
than free tPA, as demonstrated in a microfluidic chip where clots are formed
mimicking in vivo conditions. At 60 min post treatment initiation, the clot
area reduces by half (57 + 8 %) with tPA-DPNs, whereas a similar result (56 +
21 %) is obtained only after 90 min for free tPA. In murine mesentery venules,
the intravenous administration of 2.5 mg/kg of tPA-DPNs resolves almost 90 % of
the blood clots, whereas a similar dose of free tPA successfully recanalize
only about 40 % of the treated vessels. At about 1/10 of the clinical dose (1.0
mg/kg), tPA-DPNs still effectively dissolve 70 % of the clots, whereas free tPA
works efficiently only on 16 % of the vessels. In vivo, discoidal tPA-DPNs
outperform the lytic activity of 200 nm spherical tPA-coated nanoconstructs in
terms of both percentage of successful recanalization events and clot area
reduction. The conjugation of tPA with preserved lytic activity, the
deformability and blood circulating time of DPNs together with the faster blood
clot dissolution would make tPA-DPNs a promising nanotool for enhancing both
potency and safety of thrombolytic therapies.
